Patents by Inventor Douglas Alan Livingston

Douglas Alan Livingston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF
    Publication number: 20080293660
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: April 9, 2008
    Publication date: November 27, 2008
    Applicant: La Jolla Pharmaceutical Company
    Inventors: Stephen M. COUTTS, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Chemically defined non-polymeric valency platform molecules and conjugates thereof
    Patent number: 7351855
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: April 1, 2008
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Chemically-defined non-polymeric valency platform molecules and conjugates thereof
    Patent number: 7115581
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: October 3, 2006
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
    Patent number: 7002012
    Abstract: A method for the prophylaxis of an inflammatory condition or immune disorder associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I) or a solvate thereof wherein: X is —O— or —NH—; Q is (—CH2—)p, (—CH?CH—)p, (—C?C—)p where p is an integer of from 0 to 4; R1 is hydrogen or methyl; R2 and R3 independently represent O or S; n is an integer of 1 to 50; and R is hydrogen or methyl.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: February 21, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Susan Mary Daluge, Gerald Wolberg, Douglas Alan Livingston
  • Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
    Publication number: 20030181471
    Abstract: 1.
    Type: Application
    Filed: June 17, 2002
    Publication date: September 25, 2003
    Inventors: Susan Mary Daluge, Gerald Wolberg, Douglas Alan Livingston
  • Chemically-defined non-polymeric valency platform molecules and conjugates thereof
    Publication number: 20030162953
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: May 10, 2002
    Publication date: August 28, 2003
    Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl) phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
    Patent number: 6437124
    Abstract: The present invention provides a compound of formula (I) or a solvate thereof wherein: X is —O— or —NH—; Q is (—CH2—)p, (—CH═CH—)p, (—C≡C—)p where p is an integer of from 0 to 4; R1 is hydrogen or methyl; R2 and R3 independently represent O or S n is an integer of 1 to 50; and R is hydrogen or methyl. The present invention also provides pharmaceutical compositions and methods of treatment using the compounds of formula (I).
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: August 20, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Susan Mary Daluge, Gerald Wolberg, Douglas Alan Livingston
  • Conjugates of chemically defined non-polymeric valency platform molecules and biologically active molecules
    Publication number: 20020107389
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: December 29, 2000
    Publication date: August 8, 2002
    Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform molecules
    Publication number: 20020082400
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity-for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: December 29, 2000
    Publication date: June 27, 2002
    Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Therapeutic nucleosides
    Patent number: 6392085
    Abstract: The present invention relates to intermediates useful for the preparation of certain compounds, for example, purine carbocyclic nucleosides.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: May 21, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Susan Mary Daluge, Douglas Alan Livingston
  • Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)phenyl derivatives, their preparation and their use in treatment of inflammatory conditions and immune disorders
    Patent number: 6355646
    Abstract: The present invention provides a compound of formula (I) or a solvate thereof wherein: X is —O— or —NH—; Q is (—CH2—)p, (—CH═CH—)p, (—C≡C—)p where p is an integer of from 0 to 4; R1 is hydrogen or methyl; R2 and R3 independently represent O or S n is an integer of 1 to 50; and R is hydrogen or methyl. The present invention also provides pharmaceutical compositions and methods of treatment using the compounds of formula (I). The compounds of the present invention are useful for the prophylaxis and treatment of septic shock, inflammatory conditions and immune disorders.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: March 12, 2002
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Mary Daluge, Gerald Wolberg, Douglas Alan Livingston
  • THERAPEUTIC NUCLEOSIDES
    Publication number: 20010008946
    Abstract: The present invention relates to intermediates useful for the preparation of certain compounds, for example, purine carbocyclic nucleosides.
    Type: Application
    Filed: July 10, 1998
    Publication date: July 19, 2001
    Inventors: SUSAN MARY DALUGE, DOUGLAS ALAN LIVINGSTON
  • Methods for oligonucleotide synthesis
    Patent number: 6166198
    Abstract: Improved methods for solution-phase synthesis of purified short-chain oligonucleotide coupling units, such as dimers, trimers, and tetramers, suitable for use in solution-phase or solid-phase oligonucleotide synthesis are provided.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: December 26, 2000
    Assignee: La Jolla Pharmaceutical Company
    Inventor: Douglas Alan Livingston
  • Intermediates for the preparation of sulphonic acid salts of 4-amino-2-cyclopentene-1-carboxylic acid
    Patent number: 5919941
    Abstract: The present invention relates to intermediates for the preparation of sulphonic acid salts of 4-amino-2-cyclopentane-1-carboxylic acid.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: July 6, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Mary Daluge, Douglas Alan Livingston
  • Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
    Patent number: 5874552
    Abstract: Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R.sup.1 and R.sup.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: February 23, 1999
    Assignee: La Jolla Pharmaceutical Company
    Inventors: David S. Jones, John P. Hachmann, Michael J. Conrad, Stephen Coutts, Douglas Alan Livingston
  • Selective capping solution phase oligonucleotide synthesis
    Patent number: 5856464
    Abstract: Improved methods for solution-phase synthesis of purified short-chain oligonucleotide coupling units, such as dimers, trimers, and tetramers, suitable for use in solution-phase or solid-phase oligonucleotide synthesis are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 5, 1999
    Assignee: LaJolla Pharmaceutical Company
    Inventor: Douglas Alan Livingston
  • Intermediates to carbocyclic nucleosides
    Patent number: 5840990
    Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring ill place of trip sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for there preparation, pharmaceutical formulations containing them, and to the use of such compounds in therapy, particularly the treatment of or prophylaxis of certain viral infections.
    Type: Grant
    Filed: November 6, 1996
    Date of Patent: November 24, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Mary Daluge, Douglas Alan Livingston
  • Therapeutic nucleosides
    Patent number: 5808147
    Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain viral infections.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: September 15, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Mary Daluge, Douglas Alan Livingston
  • Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
    Patent number: 5786512
    Abstract: Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R.sup.1 and R.sup.
    Type: Grant
    Filed: November 8, 1994
    Date of Patent: July 28, 1998
    Assignee: LaJolla Pharmaceutical Company
    Inventors: David S. Jones, John P. Hachmann, Michael J. Conrad, Stephen Coutts, Douglas Alan Livingston
  • Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
    Patent number: 5726329
    Abstract: Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R.sup.1 and R.sup.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: March 10, 1998
    Assignee: La Jolla Pharmaceutical Company
    Inventors: David S. Jones, John P. Hachmann, Michael J. Conrad, Stephen Coutts, Douglas Alan Livingston